ClinicalTrials.gg
CompletedNCT04465851Fe-ROUTINEUpdated Jul 10, 2020

Effect of Ferrous iROn and cUrcumin sTatus on Inflammatory and Neurotrophic markErs

An interventional study of Ferrous Sulphate 65 mg and Curcumin in Iron Deficiency (Without Anemia), sponsored by University of Westminster. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-07-10.

Sponsored by University of Westminster · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Jul 2018, registered Jun 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
155
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Iron Deficiencies with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Iron Deficiencies · United Kingdom.

Enrollment
6th of 19
155 · median 50
Started
2018
the only one that year
No phase
11 of 22
1 open now
Registered
19th of 22
by date
Lead sponsor
2 of 22
University of Westminster

Among the 22 studies in Iron Deficiencies with a site in United Kingdom, this one is the 6th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2018, is one of 11 with no phase, and was the 19th registered.

Iron Deficiencies

386 studies on the registry are indexed under Iron Deficiencies; 78 are open to participants now.

Browse Iron Deficiencies studies →

Open to participants now

2 of the 22 studies in Iron Deficiencies with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 53 Iron Deficiencies studies recruiting now, 23 (43%) set no upper age limit and 26 (49%) stop at 75 or younger; 14 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Iron Deficiencies with a site in United Kingdom, or all of them as a file.
02

Study summary

INTRODUCTION: Iron is a vital nutrient for many physiological processes including DNA production, oxygen transport and neuronal processes. However, several factors limit iron absorption including: limited bioavailability of iron (dietary or supplementation sources), can be subject to dietary iron inhibitors (e.g. calcium). Excess iron can cause cellular oxidative stress in the body.

Curcumin is an active component found in turmeric, known for its anti-oxidant and anti-inflammatory properties. Co-administration of iron and curcumin may influence iron, inflammatory status and/or neurotrophic markers in the body.

Read the detailed description

Intervention study with five parallel treatment groups in a randomised, double-blind, placebo-controlled design.

Study population: Healthy Participants (Male or Female) will receive daily supplements (active or equivalent placebos) for 6 weeks (42 days)

Biological samples (blood and urine samples) are collected at baseline visit (day 1), mid-point (day 21) and end-point (day 42). In addition, pertinent questionnaires (Visual Analogue Scale-Fatigue [VAS-F] and oral iron supplement questionnaire will be collected at the aforementioned time points.

03

Conditions studied

  • Iron Deficiency (Without Anemia)

Keywords

  • nutraceutical
  • anti-oxidant
  • oxidative status
  • ferrous sulphate
  • curcumin
  • inflammatory status
  • turmeric
  • gastrointestinal
  • fatigue
  • iron
  • Hydrocurc
  • supplement
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males \& Females (18-40 years of age)
  • Healthy subjects

Exclusion criteria

Exclusion Criteria:

  • \<18 years or >40 years
  • Dieters
  • Consumption of >21 serving of alcohol/week
  • Any allergies/health issues related to items being ingested
  • Any serious illnesses or those on medication
  • Any pregnant or lactating women
  • Any women who are trying to conceive
  • Any women taking medication
  • Any gastrointestinal disorders
  • Any chronic menstrual disorders
  • Any subjects who have undergone the menopause or undergoing the perimenopause transition
  • Any eating disorders
  • Any depression/mental disorders
  • Any abnormal blood pressure levels
  • Those with deficient/excess/abnormal iron levels according to United Kingdom (UK) guidelines \&/or haemochromatosis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
155 participants (actual)

Study arms

  • Active comparator
    FS65_Curc

    Ferrous Sulphate (65 mg/day elemental iron) and Curcumin 500 mg/day

    Dietary Supplement: Ferrous Sulphate 65 mg · Dietary Supplement: Curcumin

  • Placebo comparator
    FS65_Plac

    Ferrous Sulphate (65 mg/day elemental iron) and Placebo (Curcumin placebo \[cellulose\])

    Dietary Supplement: Ferrous Sulphate 65 mg · Other: Placebo (Curcumin)

  • Placebo comparator
    FS0_Plac

    Placebo (Ferrous Sulphate placebo \[cellulose\]) and Placebo (Curcumin placebo \[cellulose\])

    Other: Placebo (Ferrous Sulphate) · Other: Placebo (Curcumin)

  • Placebo comparator
    FS18_Plac

    Ferrous Sulphate (18 mg/day elemental iron) and Placebo (Curcumin placebo \[cellulose\])

    Other: Placebo (Curcumin) · Dietary Supplement: Ferrous Sulphate 18mg

  • Active comparator
    FS18_Curc

    Ferrous Sulphate (18 mg/day elemental iron) and Curcumin 500 mg/day

    Dietary Supplement: Curcumin · Dietary Supplement: Ferrous Sulphate 18mg

Interventions

  • Dietary supplementFerrous sulfateStudies of Ferrous sulfateFerrous sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral ferrous salt supplement Ferrous Sulphate 200 mg (equiv. 65 mg elemental iron content) Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules

    Also known as: Ferrous Sulfate

  • Dietary supplementCurcumin

    HydroCurc™ 500 mg formulated curcumin At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)

    Also known as: Turmeric, Curcuma longa

  • OtherPlacebo (Ferrous Sulphate)

    Microcrystalline cellulose Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)

  • OtherPlacebo (Curcumin)

    Microcrystalline cellulose Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach)

  • Dietary supplementFerrous sulfateStudies of Ferrous sulfateFerrous sulfate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oral ferrous salt supplement Ferrous Sulphate 55 mg (equiv. 18 mg elemental iron content) Participants instructed to swallow opaque capsules with water away from meals (on an empty stomach) At the mid-point visit day (day 21) and the finally at the end-point (day 42) compliance will be verified by counting capsules

    Also known as: Ferrous Sulfate

06

What researchers measure

Primary outcomes

  1. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation

    Marker: Interleukin 6 (pg/mL), Interleukin 10 (pg/mL), Interleukin 1 beta (pg/mL)

    Time frame: Change in Interleukin 6, Interleukin 10 and Interleukin 1 beta (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  2. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation

    Tumour Necrosis Factor alpha (pg/mL)

    Time frame: Change in Tumour Necrosis Factor alpha (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  3. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated inflammation

    Marker: C-Reactive Protein (g/L)

    Time frame: Change in C-Reactive Protein (immunoassay) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  4. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated lipid peroxidation

    Marker: thiobarbituric acid reactive substances (μM)

    Time frame: Change in thiobarbituric acid reactive substances (ELISA) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  5. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated acute iron absorption

    Marker: serum iron (μmol/L)

    Time frame: Change in serum iron (colorimetric analyser) from 0 and 180 minutes following supplementation

  6. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated acute iron absorption

    Marker: total iron binding capacity (μmol/L)

    Time frame: Change in total iron binding capacity (colorimetric analyser) from 0 and 180 minutes following supplementation

  7. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status

    Marker: serum iron (μmol/L)

    Time frame: Change in serum iron (colorimetric analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  8. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status

    Marker: total iron binding capacity (μmol/L)

    Time frame: Change in total iron binding capacity (colorimetric analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  9. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status

    Marker: Ferritin (ng/mL)

    Time frame: Change in ferritin (immunoassay) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  10. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status

    Marker: Haemoglobin (g/dL)

    Time frame: Change in haemoglobin (whole blood analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  11. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated iron status

    Marker: Red blood cells (M/μL)

    Time frame: Change in red blood cells (whole blood analyser) from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

Secondary outcomes

  1. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated neurotrophic levels

    Marker: Brain derived neurotrophic factor (BDNF) (ng/mL)

    Time frame: Change in BDNF (ELISA) from baseline to endpoint from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  2. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated gastrointestinal effects

    Subjective analysis including: Oral Iron Supplement Questionnaire

    Time frame: Change in reported subjective gastrointestinal effects from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  3. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated perception of fatigue

    Subjective analysis including: Visual Analogue Scale for Fatigue (VAS-F). Scores range from 0 to 100 (the higher the score the greater the level of fatigue)

    Time frame: Change in VAS-F from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

  4. To assess the influence of HydroCurc™ administration on ferrous iron supplementation associated perception of fatigue

    Subjective analysis including: Fatigue Severity Scale (FSS). The total score of all answers indicates level of fatigue (a total score above ≥ 36 indicates fatigue).

    Time frame: Change in FSS from day 1 compared to day 21 (baseline to midpoint), day 1 compared to day 42 (baseline to endpoint) and day 21 compared to day 42 (midpoint to endpoint)

07

Study locations

1 site
  • University of Westminster
    London, W1W 6UW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Nov 2019, 15 months.

Of 77 non-industry interventional studies with no phase under Iron Deficiencies, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 15 months is above that.

Counting every sponsor, half of 89 studies reached it within 10 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jul 10, 2020
StartActual
Jul 18, 2018
Primary completionActual
Nov 11, 2019
CompletionActual
Jan 31, 2020
Last update
Jul 10, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04465851
Lead sponsor
University of Westminster
Collaborators
Gencor Pacific Group
Responsible party
Mohammed Gulrez Zariwala (Reader in Translational Physiology, University of Westminster) — Principal investigator
First posted
Jul 10, 2020
Start date
Jul 18, 2018
Primary completion
Nov 11, 2019
Completion
Jan 31, 2020
Last update
Jul 10, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Curcumin

Start the discussion